中文
In Focus
Snapshots
News Bites
中文
SEARCH RESULTS
To create your individual collection of articles for download, tick the relevant boxes and click the download button below.
Year
ALL
2021
2022
Business Unit
ALL
Corporate
Ports
Retail
Infrastructure
Energy
Telecoms
Other Business
LKSF
03.2022
Snapshots
HUTCHMED cancer drugs added to the Chinese list of reimbursable treatments
China’s National Reimbursement Drug List aims to make life-saving drugs accessible to citizens in Mainland China and has expanded the number of HUTCHMED medicines on the list. The latest to be included is SULANDA® (surufatinib), following its approval for the treatment of advanced pancreatic neuroendocrine tumours. This latest update of the list also renewed ELUNATE® (fruquintinib), first included in 2020, for the treatment of metastatic colorectal cancer.
Related:
Others
HUTCHMED
R&D
Select for Download
03.2022
Snapshots
HUTCHMED joins global, industry stock benchmark indices
HUTCHMED is now a constituent stock in the FTSE Russell’s Global Equity Index Series (GEIS), including FTSE All-World, FTSE Global All Cap, FTSE Global Total Cap and FTSE Global Mid Cap Indexes. The GEIS monitors more than 16,000 stocks in over 70 countries representing 98% of global market cap, making it a key indicator of global stock market direction.
Related:
Others
HUTCHMED
Select for Download
>> PREVIOUS STORIES
Download
Create a PDF of your selected
stories and download
Copied to clipboard
Downloading PDF. Please wait...
Copied to clipboard
Downloading PDF. Please wait...
Subscribe for updates
I have read and accepted the
Terms & Conditions
and the
Privacy Policy
of this website.
Subscribe
Scroll